

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 Jun 2026

The effect of alcoholic extract of the olive leaf on clinical and Laboratory outcomes of patients with Covid-19

Protocol summary

Study aim

Determining the effect of olive leaf extract on clinical and laboratory outcomes of patients with Covid-19

Design

A randomized, three-sided, randomized controlled clinical trial on 129 patients was used using the randomized block method of Excel software.

Settings and conduct

The study population is all patients with Covid-19 hospitalized in the general wards of Shahid Labbafinejad Hospital in Tehran. The groups will evaluate the participants in terms of age, sex, and lung involvement with a standardized block block. The researcher will evaluate the study participants using a clinical outcome questionnaire and a laboratory findings questionnaire. Then he puts the medicine packages that he, the patient and the statistics consultant are unaware of in the participants' medicine box and asks the ward nurses to provide the medicine to the participants twice a day for 5 days.

Participants/Inclusion and exclusion criteria

Admission: All patients with Covid - 19 approved by the doctor - Age 18-70 years - Level of consciousness 15
Withdrawal: taking supplements containing oleopurine - any underlying disease - pregnancy and lactation - hypoglycemia - hypotension - unwillingness to cooperate - allergies - not taking the right medication

Intervention groups

Olive leaf extract group at a dose of 250 mg twice a day for five days Olive leaf extract group at a dose of 500 mg twice a day for five days control group Use of wheat placebo in capsules of the same shape with intervention groups twice a day for five days

Main outcome variables

Temperature, blood pressure, heart rate, percentage of arterial oxygen saturation

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20201128049520N1**

Registration date: **2021-02-22, 1399/12/04**

Registration timing: **prospective**

Last update: **2021-02-22, 1399/12/04**

Update count: **0**

Registration date

2021-02-22, 1399/12/04

Registrant information

Name

Elham Ahmadpour

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 66 3341 3823

Email address

elhamahmadpour10@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-03-05, 1399/12/15

Expected recruitment end date

2021-06-22, 1400/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of alcoholic extract of the olive leaf on clinical and Laboratory outcomes of patients with Covid-19

Public title

effect of olive leaf extract on Covid-19 patients

Purpose

Supportive

Inclusion/Exclusion criteria**Inclusion criteria:**

All patients with Quid-19 based on standard diagnostic test (positive PCR test, CT scan of lung) approved by infectious disease specialist Age range is 18 to 70 years Have a level of consciousness of 15 according to the Glasgow standard

Exclusion criteria:

Take oleopurine supplements 3 months before the study
Use of mechanical ventilation equipment
Existence of underlying respiratory diseases such as COPD, asthma
Taking anti-hypertensive, anti-platelet and anti-diabetic drugs
Pregnancy and lactation
Immune system deficiency or the use of immunosuppressive drugs
Malignancies
Presence of heart, kidney, liver, blood pressure, diabetes and corticosteroid disorders
Reluctance to continue cooperation
The patient is discharged earlier than the completion of the treatment period
Hypotension (mean arterial pressure less than 70 mm Hg)
Hypoglycemia (blood sugar less than 75 mg / dL)
Existence of allergies to drugs before and during the study
Lack of proper use of drugs
The need for therapeutic interventions other than the usual therapeutic interventions during research such as the need for dialysis, angioplasty and ...
Participate in other research that in any way affects the results of the research

Age

From **18 years** old to **70 years** old

Gender

Both

Phase

2-3

Groups that have been masked

- Participant
- Investigator
- Data analyser

Sample size

Target sample size: **129**

Randomization (investigator's opinion)

Randomized

Randomization description

Allocation of samples in study groups by random blocking method

Blinding (investigator's opinion)

Triple blinded

Blinding description

Capsules containing olive leaf extract in two doses of 250 and 500 mg and placebo are exactly the same in terms of color, shape and size and are coded and packaged by another person without the knowledge of the researcher, analyst and participant The contents of the capsule will be placed in the participants' medicine boxes. Before the start of the study and when informed consent is obtained

from the participant, they are informed that they are randomly placed in one of the intervention or control groups. Before the start of the study and when informed consent is obtained from the participant, they are informed that they are randomly placed in one of the intervention or control groups.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Lorestan University of Medical Sciences

Street address

University of Medical Sciences, Shahid Anoushirvan Rezaei Square, Moallem St, Khorramabad

City

Khorramabad

Province

Lorestan

Postal code

6813833946

Approval date

2021-02-15, 1399/11/27

Ethics committee reference number

IR.LUMS.REC.1399.262

Health conditions studied**1****Description of health condition studied**

COVID - 19

ICD-10 code

B34.2

ICD-10 code description

Coronavirus infection, unspecified

Primary outcomes**1****Description**

Arterial oxygen saturation

Timepoint

Before starting the intervention, then for five days twice a day from 6 am to 6 pm

Method of measurement

Medair pulse oximeter device

2

Description

Heart rate

Timepoint

Before starting the intervention, then for five days twice a day from 6 am to 6 pm

Method of measurement

pulse oximeter device

3

Description

Temperatures

Timepoint

Before starting the intervention, then for five days twice a day from 6 am to 6 pm

Method of measurement

Digital thermometer

4

Description

blood pressure

Timepoint

Before starting the intervention, then for five days twice a day from 6 am to 6 pm

Method of measurement

Hand pressure gauge

5

Description

Complete blood count

Timepoint

Before and during the intervention on a daily basis

Method of measurement

Patient file

Secondary outcomes

1

Description

Severity of general symptoms of Covid-19 disease

Timepoint

Before and during the intervention on a daily basis

Method of measurement

Symptom Severity Questionnaire

2

Description

Duration of hospitalization

Timepoint

Patient discharge time

Method of measurement

Counting the number of days the patient is hospitalized

Intervention groups

1

Description

Intervention group: Patients who at the same time with standard treatments, capsules containing olive leaf extract (capsules with a dose of 250 mg twice a day for five days) olive leaf extract by Rose Daru Pharmaceutical Company in drug capsules of the same shape and size as other groups The intervention will be prepared and stored in conditions away from light and moisture.

Category

Treatment - Drugs

2

Description

Intervention group: Patients who at the same time with standard treatments, capsules containing olive leaf extract (capsules with a dose of 500 mg twice a day for five days) olive leaf extract by Rose Daru Pharmaceutical Company in drug capsules of the same shape and size as other groups The intervention will be prepared and stored in conditions away from light and moisture.

Category

Treatment - Drugs

3

Description

Control group: Patients who receive placebo at the same time as standard treatments in the form of capsules containing wheat flour twice a day for five days. The placebo will be stored by Rose Drug Pharmaceutical Company in drug capsules of the same shape and size as the other intervention groups prepared away from light and moisture.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Labbafinejad hospital

Full name of responsible person

Elham Ahmadpour

Street address

Shahid Labbafinejad hospital, 9th Bosthan Alley, Pasdaran St.

City

Tehran

Province

Tehran

Postal code

1666663111

Phone

+98 21 23601

Email

elhamahmadpour10@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Khoram-Abad University of Medical Sciences

Full name of responsible person

Ebrahim Fallahi

Street address

University of Medical Sciences, Shahid Anoushirvan
Rezaei Square, Moallem St, Khorramabad

City

Khorramabad

Province

Lorestan

Postal code

381251698

Phone

+98 66 3341 3823

Fax

+98 66 3312 0173

Email

research@lums.ac.ir

Web page address

http://research.lums.ac.ir/index.php?module=web_directory&wd_id=4664

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Khoram-Abad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact**Name of organization / entity**

Khoram-Abad University of Medical Sciences

Full name of responsible person

Elham Ahmadpour

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Nursery

Street address

University of Medical Sciences, Shahid Anoushirvan
Rezaei Square, Moallem St, Khorramabad

City

Khorramabad

Province

Lorestan

Postal code

381251698

Phone

+98 66 3341 3823

Email

elhamahmadpour10@gmail.com

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Khoram-Abad University of Medical Sciences

Full name of responsible person

Elham Ahmadpour

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Nursery

Street address

University of Medical Sciences, Shahid Anoushirvan
Rezaei Square, Moallem St, Khorramabad

City

Khorramabad

Province

Lorestan

Postal code

381251698

Phone

+98 66 3341 3823

Fax

+98 66 3312 0173

Email

elhamahmadpour10@gmail.com

Person responsible for updating data

Contact**Name of organization / entity**

Khoram-Abad University of Medical Sciences

Full name of responsible person

Elham Ahmadpour

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Nursery

Street address

University of Medical Sciences, Shahid Anoushirvan
Rezaei Square, Moallem St, Khorramabad

City

Khorramabad

Province

Lorestan

Postal code

381251698

Phone

+98 66 3341 3823

Fax

+98 66 3312 0173

Email

elhamahmadpour10@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to

make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available